Commentary

TikTok’s fave weight loss drugs: Link to thyroid cancer?


 

How to advise our patients and respond to the EMR messages

The TikTok videos may continue, the celebrity chatter may increase, and we, as physicians, will continue to look to real-world data with randomized controlled trials to tailor our decision-making and guide our patients.

It’s prudent to advise patients that if they have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, in particular, they should avoid using this class of medication. Thyroid cancer remains a rare outcome, and GLP-1 receptor agonists remain a very important and beneficial treatment option for the right patient.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

USPSTF holds firm on postmenopausal hormone recommendations
MDedge Endocrinology
Thyroid nodule volume reduction correlates with energy in ablation
MDedge Endocrinology
‘Game changer’: Thyroid cancer recurrence no higher with lobectomy
MDedge Endocrinology
Lifestyle choices could curb genetic risk for thyroid cancer
MDedge Endocrinology
Guidance updated for congenital hypothyroidism screening, management
MDedge Endocrinology
New consensus on thyroid eye disease prompts some debate
MDedge Endocrinology
Commenting on weight’s not rude. It’s dangerous.
MDedge Endocrinology
Taking a break from TKIs unlikely to shorten survival
MDedge Endocrinology
What do high BUN/Cr ratios mean?
MDedge Endocrinology
What’s it like to take Ozempic? A doctor’s own story
MDedge Endocrinology